Last reviewed · How we verify
Melphalan/Prednisone/Velcade
This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone therapy with bortezomib/Velcade (proteasome inhibitor) to kill multiple myeloma cells through DNA damage, immunosuppression, and disruption of protein degradation pathways.
This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone therapy with bortezomib/Velcade (proteasome inhibitor) to kill multiple myeloma cells through DNA damage, immunosuppression, and disruption of protein degradation pathways. Used for Multiple myeloma (newly diagnosed, elderly or transplant-ineligible patients).
At a glance
| Generic name | Melphalan/Prednisone/Velcade |
|---|---|
| Sponsor | PETHEMA Foundation |
| Drug class | Combination chemotherapy (alkylating agent + corticosteroid + proteasome inhibitor) |
| Target | DNA (melphalan); glucocorticoid receptor (prednisone); 26S proteasome (bortezomib/Velcade) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Melphalan damages DNA in rapidly dividing myeloma cells. Prednisone provides immunosuppressive and anti-inflammatory effects. Bortezomib inhibits the 26S proteasome, preventing degradation of pro-apoptotic proteins and causing accumulation of misfolded proteins, leading to myeloma cell death. The three-drug combination targets multiple pathways to overcome drug resistance.
Approved indications
- Multiple myeloma (newly diagnosed, elderly or transplant-ineligible patients)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Peripheral neuropathy
- Infection
- Nausea/vomiting
- Fatigue
Key clinical trials
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (PHASE4)
- A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma (PHASE3)
- A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens (PHASE2)
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma (PHASE1)
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) (PHASE3)
- Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone (PHASE2)
- Bortezomib With Melphalan and Prednisone for Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |